In this Q&A, Carly Stafford Dixon discusses her lymphoma journey, recovery with CAR T therapy, and mission to raise support ...

Researchers sought to assess the access to CAR-T therapy for patients within community-based and transplant cell therapy networks.

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL ... It is the most common form of non-Hodgkin lymphoma (NHL), accounting for ...

The results of the phase 2 NP30179 study will be presented for the first time at ASCO, involving 107 patients with relapsed or refractory diffuse large B-cell ... form of non-Hodgkin lymphoma ...

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell ...

Gerald Voelbel, 57, a cognitive neuroscientist, awoke with double vision, a migraine, and coordination issues—symptoms that led to two unexpected diagnoses.

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first neuro ...

Vietnamese and US descendants of those exposed to Agent Orange continue to face diseases and congenital anomalies.

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Patients with primary cutaneous B-cell lymphoma showed a higher risk of developing prostate and hematologic cancers in a ...

Apr. 29, 2025 — A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete ...